Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing

Johannes Khinast, Michael Leane, Kendal Pitt, Gavin K. Reynolds, Neil Dawson, Iris Ziegler, Aniko Szepes, Abina M. Crean, Rafaela Dall Agnol, Bianca Broegmann, Stuart Charlton, Conrad Davies, John Gamble, Michael Gamlen, Wen Kai Hsiao, Yaroslav Khimyak, Peter Kleinebudde, Chris Moreton, Mira Oswald, Susanne Page & 5 others Amrit Paudel, Ranjita Sahoo, Stephen Sheehan, Howard Stamato, Elaine Stone

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Following the first Manufacturing Classification System (MCS) paper, the team conducted surveys to establish which active pharmaceutical ingredient (API) properties were important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. The most commonly identified factors were (1) API particle size: small particle sizes are known to increase risk of processing issues; (2) Drug loading in the formulation: high drug loadings allow less opportunity to mitigate poor API properties through the use of excipients. The next step was to establish linkages with process decisions by identifying publicly-available proxies for these important parameters: dose (in place of drug loading) and BCS class (in place of particle size). Poorly-soluble API were seen as more likely to have controlled (smaller) particle size than more highly soluble API. Analysis of 435 regulatory filings revealed that higher doses and more poorly-soluble API was associated with more complex processing routes. Replacing the proxy factors with the original parameters should give the opportunity to demonstrate stronger trends. This assumption was tested by accessing a dataset relating to commercial tablet products. This showed that, for dry processes, a larger particle size was associated with higher achievable drug loading as determined by percolation threshold.
Original languageEnglish
Pages (from-to)964-977
Number of pages13
JournalPharmaceutical development and technology
DOIs
Publication statusPublished - 2018

Fingerprint

Industry
Particle Size
Pharmaceutical Preparations
Proxy
Drug Compounding
Excipients
Tablets

Keywords

  • Drug product manufacturing processes
  • oral solid dosage forms
  • pharmaceutical development
  • quality by design
  • drug substance
  • continuous processing

Cite this

Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing. / Khinast, Johannes; Leane, Michael; Pitt, Kendal ; Reynolds, Gavin K.; Dawson, Neil; Ziegler, Iris; Szepes, Aniko; Crean, Abina M.; Agnol, Rafaela Dall; Broegmann, Bianca; Charlton, Stuart; Davies, Conrad; Gamble, John; Gamlen, Michael; Hsiao, Wen Kai; Khimyak, Yaroslav; Kleinebudde, Peter; Moreton, Chris; Oswald, Mira; Page, Susanne; Paudel, Amrit; Sahoo, Ranjita; Sheehan, Stephen ; Stamato, Howard; Stone, Elaine.

In: Pharmaceutical development and technology, 2018, p. 964-977.

Research output: Contribution to journalArticleResearchpeer-review

Khinast, J, Leane, M, Pitt, K, Reynolds, GK, Dawson, N, Ziegler, I, Szepes, A, Crean, AM, Agnol, RD, Broegmann, B, Charlton, S, Davies, C, Gamble, J, Gamlen, M, Hsiao, WK, Khimyak, Y, Kleinebudde, P, Moreton, C, Oswald, M, Page, S, Paudel, A, Sahoo, R, Sheehan, S, Stamato, H & Stone, E 2018, 'Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing' Pharmaceutical development and technology, pp. 964-977. https://doi.org/10.1080/10837450.2018.1534863
Khinast, Johannes ; Leane, Michael ; Pitt, Kendal ; Reynolds, Gavin K. ; Dawson, Neil ; Ziegler, Iris ; Szepes, Aniko ; Crean, Abina M. ; Agnol, Rafaela Dall ; Broegmann, Bianca ; Charlton, Stuart ; Davies, Conrad ; Gamble, John ; Gamlen, Michael ; Hsiao, Wen Kai ; Khimyak, Yaroslav ; Kleinebudde, Peter ; Moreton, Chris ; Oswald, Mira ; Page, Susanne ; Paudel, Amrit ; Sahoo, Ranjita ; Sheehan, Stephen ; Stamato, Howard ; Stone, Elaine. / Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing. In: Pharmaceutical development and technology. 2018 ; pp. 964-977.
@article{ccbeaaec8ae24893a0837a9ddfe5fc4c,
title = "Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing",
abstract = "Following the first Manufacturing Classification System (MCS) paper, the team conducted surveys to establish which active pharmaceutical ingredient (API) properties were important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. The most commonly identified factors were (1) API particle size: small particle sizes are known to increase risk of processing issues; (2) Drug loading in the formulation: high drug loadings allow less opportunity to mitigate poor API properties through the use of excipients. The next step was to establish linkages with process decisions by identifying publicly-available proxies for these important parameters: dose (in place of drug loading) and BCS class (in place of particle size). Poorly-soluble API were seen as more likely to have controlled (smaller) particle size than more highly soluble API. Analysis of 435 regulatory filings revealed that higher doses and more poorly-soluble API was associated with more complex processing routes. Replacing the proxy factors with the original parameters should give the opportunity to demonstrate stronger trends. This assumption was tested by accessing a dataset relating to commercial tablet products. This showed that, for dry processes, a larger particle size was associated with higher achievable drug loading as determined by percolation threshold.",
keywords = "Drug product manufacturing processes, oral solid dosage forms, pharmaceutical development, quality by design, drug substance, continuous processing",
author = "Johannes Khinast and Michael Leane and Kendal Pitt and Reynolds, {Gavin K.} and Neil Dawson and Iris Ziegler and Aniko Szepes and Crean, {Abina M.} and Agnol, {Rafaela Dall} and Bianca Broegmann and Stuart Charlton and Conrad Davies and John Gamble and Michael Gamlen and Hsiao, {Wen Kai} and Yaroslav Khimyak and Peter Kleinebudde and Chris Moreton and Mira Oswald and Susanne Page and Amrit Paudel and Ranjita Sahoo and Stephen Sheehan and Howard Stamato and Elaine Stone",
year = "2018",
doi = "10.1080/10837450.2018.1534863",
language = "English",
pages = "964--977",
journal = "Pharmaceutical development and technology",
issn = "1083-7450",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Manufacturing classification system in the real world: factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing

AU - Khinast, Johannes

AU - Leane, Michael

AU - Pitt, Kendal

AU - Reynolds, Gavin K.

AU - Dawson, Neil

AU - Ziegler, Iris

AU - Szepes, Aniko

AU - Crean, Abina M.

AU - Agnol, Rafaela Dall

AU - Broegmann, Bianca

AU - Charlton, Stuart

AU - Davies, Conrad

AU - Gamble, John

AU - Gamlen, Michael

AU - Hsiao, Wen Kai

AU - Khimyak, Yaroslav

AU - Kleinebudde, Peter

AU - Moreton, Chris

AU - Oswald, Mira

AU - Page, Susanne

AU - Paudel, Amrit

AU - Sahoo, Ranjita

AU - Sheehan, Stephen

AU - Stamato, Howard

AU - Stone, Elaine

PY - 2018

Y1 - 2018

N2 - Following the first Manufacturing Classification System (MCS) paper, the team conducted surveys to establish which active pharmaceutical ingredient (API) properties were important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. The most commonly identified factors were (1) API particle size: small particle sizes are known to increase risk of processing issues; (2) Drug loading in the formulation: high drug loadings allow less opportunity to mitigate poor API properties through the use of excipients. The next step was to establish linkages with process decisions by identifying publicly-available proxies for these important parameters: dose (in place of drug loading) and BCS class (in place of particle size). Poorly-soluble API were seen as more likely to have controlled (smaller) particle size than more highly soluble API. Analysis of 435 regulatory filings revealed that higher doses and more poorly-soluble API was associated with more complex processing routes. Replacing the proxy factors with the original parameters should give the opportunity to demonstrate stronger trends. This assumption was tested by accessing a dataset relating to commercial tablet products. This showed that, for dry processes, a larger particle size was associated with higher achievable drug loading as determined by percolation threshold.

AB - Following the first Manufacturing Classification System (MCS) paper, the team conducted surveys to establish which active pharmaceutical ingredient (API) properties were important when selecting or modifying materials to enable an efficient and robust pharmaceutical manufacturing process. The most commonly identified factors were (1) API particle size: small particle sizes are known to increase risk of processing issues; (2) Drug loading in the formulation: high drug loadings allow less opportunity to mitigate poor API properties through the use of excipients. The next step was to establish linkages with process decisions by identifying publicly-available proxies for these important parameters: dose (in place of drug loading) and BCS class (in place of particle size). Poorly-soluble API were seen as more likely to have controlled (smaller) particle size than more highly soluble API. Analysis of 435 regulatory filings revealed that higher doses and more poorly-soluble API was associated with more complex processing routes. Replacing the proxy factors with the original parameters should give the opportunity to demonstrate stronger trends. This assumption was tested by accessing a dataset relating to commercial tablet products. This showed that, for dry processes, a larger particle size was associated with higher achievable drug loading as determined by percolation threshold.

KW - Drug product manufacturing processes

KW - oral solid dosage forms

KW - pharmaceutical development

KW - quality by design

KW - drug substance

KW - continuous processing

U2 - 10.1080/10837450.2018.1534863

DO - 10.1080/10837450.2018.1534863

M3 - Article

SP - 964

EP - 977

JO - Pharmaceutical development and technology

JF - Pharmaceutical development and technology

SN - 1083-7450

ER -